Tegoprubart preserves kidney function better than tacrolimus in first-time transplant patients, trial suggests
A phase 2 clinical trial indicates that the drug tegoprubart is more effective than the current standard, tacrolimus, at preserving kidney function in transplant patients. Patients using the new therapy also reported better quality of life and fewer side effects.
Why it matters
This could lead to a new standard of care for transplant patients, reducing the severe side effects associated with current immunosuppressive drugs.
edited by Gaby Clark , reviewed by Robert Egan
This article has been reviewed according to Science X's editorial process and policies . Editors have highlighted the following attributes while ensuring the content's credibility:
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in